A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/13/2011	WO2011125911A1 Metal complexes and anticancer agents comprising same as active ingredient
10/13/2011	WO2011125600A1 Method and device for cell activation
10/13/2011	WO2011125469A1 Micro-rna-regulated recombinant vaccinia virus and utilization thereof
10/13/2011	WO2011125331A1 Metal salen complex derivative and process for production thereof
10/13/2011	WO2011125245A1 Method for prediction of prognosis of small cell lung cancer, method for treatment of small cell lung cancer, method for amelioration of prognosis of small cell lung cancer, and method for screening for therapeutic agent for small cell lung cancer, each utilizing mirna
10/13/2011	WO2011125139A1 Cluap1 peptides and vaccines including the same
10/13/2011	WO2011124580A1 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
10/13/2011	WO2011124087A1 Oxadiazole-based piperazine derivatives and applications thereof
10/13/2011	WO2011124063A1 Polypeptides for the treatment or prevention of cancers and uses thereof
10/13/2011	WO2011124031A1 Polypeptide conjugate of paclitaxel or docetaxel
10/13/2011	WO2011123946A1 Kinase inhibitors and method of treating cancer with same
10/13/2011	WO2011123942A1 Fatty acid derivatives of catechins and methods of their use
10/13/2011	WO2011123937A1 Kinase inhibitors and method of treating cancer with same
10/13/2011	WO2011123911A1 Antitumoral compounds of testosterone and chemotherapeutic drugs
10/13/2011	WO2011086412A3 Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof
10/13/2011	WO2011082266A3 Substituted heterocyclic compounds
10/13/2011	WO2011071981A3 Anti-cytomegalovirus activity of artemisinin-derived dimers
10/13/2011	WO2011069149A3 Cathepsin s inhibitors
10/13/2011	WO2011068546A3 Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling
10/13/2011	WO2011066379A3 METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION
10/13/2011	WO2011059586A3 Multifunctional small molecules
10/13/2011	WO2011049412A3 Human recombinant monoclonal antibody that specifically binds to vcam-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
10/13/2011	WO2011049332A3 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
10/13/2011	WO2011031890A4 Cancer stem cell-targeted and drug resistant cancer therapy
10/13/2011	WO2011009903A3 Material system comprising endoperoxide adapting to decomposition, and applications
10/13/2011	US20110251593 In Vivo and Ex Vivo Expansion of Hematopoietic Stem Cells With a Targeted Combination of Clinically Tested, FDA Approved Drugs
10/13/2011	US20110251289 New compounds for the treatment of cancer
10/13/2011	US20110251274 Natural Vitamin E Compositions with Superior Antioxidant Potency
10/13/2011	US20110251269 Preparation method of polymeric micelles composition containing a poorly water-soluble drug
10/13/2011	US20110251263 RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof
10/13/2011	US20110251261 Compositions and methods for inhibition of nucleic acids function
10/13/2011	US20110251259 Compositions and methods for inhibiting expression of cd274/pd-l1 gene
10/13/2011	US20110251255 Methods and Compositions for Inhibiting the Proliferation of Cancer Cells
10/13/2011	US20110251252 Biomarkers for mdm2 inhibitors for use in treating disease
10/13/2011	US20110251246 Small molecule inhibitors of muc1 and methods of identifying the same
10/13/2011	US20110251240 Dosing Regimen of Flavopiridol for Treating Cancer
10/13/2011	US20110251226 Cyclohexylamin isoquinolone derivatives
10/13/2011	US20110251224 Spiro-oxindole compounds and their uses as therapeutic agents
10/13/2011	US20110251222 Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine
10/13/2011	US20110251220 Pharmaceutical compositions comprising gamma secretase modulators
10/13/2011	US20110251217 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
10/13/2011	US20110251216 Compositions and methods for inhibiting ezh2
10/13/2011	US20110251215 Macrocyclic compounds and their use as kinase inhibitors
10/13/2011	US20110251211 Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
10/13/2011	US20110251206 Squaramide derivatives as CXCR2 antagonist
10/13/2011	US20110251202 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors
10/13/2011	US20110251200 Aryl guanidine f1f0-atpase inhibitors and related methods
10/13/2011	US20110251199 Nitrogen-containing bicyclic heteroaryl compounds and methods of use
10/13/2011	US20110251197 Lysosomotropic inhibitors of acid ceramidase
10/13/2011	US20110251194 Antineoplastic derivatives, preparation thereof and therapeutic use thereof
10/13/2011	US20110251191 Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
10/13/2011	US20110251189 Hypoxia targeted compounds for cancer diagnosis and therapy
10/13/2011	US20110251188 Acenaphtho heterocycle compounds, cyclodextrin inclusion compounds and complexes, and uses in the manufactures of bh3 protein analogue, bcl-2 family protein inhibitors thereof
10/13/2011	US20110251184 Substituted hydroxamic acids and uses thereof
10/13/2011	US20110251182 Agents and methods for treating ischemic and other diseases
10/13/2011	US20110251181 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
10/13/2011	US20110251179 3,4-DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES
10/13/2011	US20110251176 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
10/13/2011	US20110251174 2,4-diamino-pyrimidines as aurora inhibitors
10/13/2011	US20110251171 Heterocyclic compounds and methods of use
10/13/2011	US20110251170 New polymorphic form of 1-(4--2-ethyl-benzyl)-azetidine-3-carboxylic
10/13/2011	US20110251168 3-aminopyrrolidine derivatives as modulators of chemokine receptors
10/13/2011	US20110251159 Phosphoramidate Alkylator Prodrugs
10/13/2011	US20110251150 Targeting MicroRNAs For The Treatment Of Liver Cancer
10/13/2011	US20110251144 Molecular modulators of the wnt/beta-catenin pathway
10/13/2011	US20110251143 Stable elsamitrucin salt formulations
10/13/2011	US20110251140 Peptide antagonist of interleukin-15 activity
10/13/2011	US20110251138 Lipoic acid metabolite conjugate: preparation and their therapeutic effect
10/13/2011	US20110251135 Inhibitors of peritoneal seeding of cancer cells
10/13/2011	US20110251134 Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
10/13/2011	US20110251122 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
10/13/2011	US20110251120 Antimicrobial Peptides and Methods of Identifying the Same
10/13/2011	US20110250693 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
10/13/2011	US20110250650 Lentiviral vectors for the preparation of immunotherapeutical compositions
10/13/2011	US20110250292 Composition for improving radiotherapy for cancer
10/13/2011	US20110250287 One step removal of selected molecules from body fluid and tissue
10/13/2011	US20110250261 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
10/13/2011	US20110250259 Method of treating and preventing breast diseases and breast cancer with medicated formula
10/13/2011	US20110250258 Tumor-specific delivery of therapeutic agents via liposomase
10/13/2011	US20110250255 Drug coated stent with endosome-disrupting conjugate
10/13/2011	US20110250243 Nanoparticle compositions
10/13/2011	US20110250240 Immune enhancing compositions and methods of use thereof
10/13/2011	US20110250234 Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof
10/13/2011	US20110250233 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
10/13/2011	US20110250230 Cell capable of expressing exogenous gitr ligand
10/13/2011	US20110250229 Allogeneic cancer cell-based immunotherapy
10/13/2011	US20110250228 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
10/13/2011	US20110250226 Composition containing extracts of fuscoporia obliqua, ganoderma lucidum and phellinus linteus for promoting the proliferation of hematopoietic stem cells
10/13/2011	US20110250225 Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
10/13/2011	US20110250224 Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines
10/13/2011	US20110250219 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
10/13/2011	US20110250218 Disease-Associated Antigens and Methods of Use Thereof
10/13/2011	US20110250216 Methods for killing psma-expressing, taxane-resistant cancer cells
10/13/2011	US20110250213 Antibodies to cd122
10/13/2011	US20110250211 Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
10/13/2011	US20110250210 Neutralizing Antibodies and Fragments Thereof Directed Against Platelet Factor-4 Variant 1 (PF4V1)
10/13/2011	US20110250209 Inhibition of plgf to treat philadelphia chromosome positive leukemia
10/13/2011	US20110250204 Methods and compositions for diagnosing and treating diseases
10/13/2011	US20110250203 Anti-cd5 antibodies
10/13/2011	US20110250201 Antagonists of il-6 to raise albumin and/or lower crp

1 ... 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 ... 2211